ClinicalTrials.gg
Active, not recruitingNCT03241537Updated Nov 27, 2023

COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer

A Phase 3 interventional study of Intensity modulated radiotherapy in Prostate Neoplasm, sponsored by Samsung Medical Center. Active, not recruiting at 1 site in Korea, Republic of. Open to male participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-27.

Sponsored by Samsung Medical Center · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Jan 2016, registered Jul 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
20 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 198 studies in Prostatic Neoplasms with a site in Korea, Republic of — 48 open to participants now, 81 under way, 37 of them phase 3. Prostatic Neoplasms · Korea, Republic of.

Enrollment
121st of 165
61 · median 208
Started
2016
with 11 others
Phase 3
67 of 198
12 open now
Primary completion
2026-12
later than 27 of 80 live
Registered
81st of 198
by date

Among the 198 studies in Prostatic Neoplasms with a site in Korea, Republic of, this one is the 121st largest by enrollment of the 165 interventional ones that give a count, is one of 12 that started in 2016, is one of 67 in phase 3, reaches primary completion later than 27 of the 80 other live ones, and was the 81st registered.

Prostatic Neoplasms

7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

48 of the 198 studies in Prostatic Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 20 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Prostatic Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

In local advanced prostate cancer patients with clinically positive metastatic regional lymph node, the optimal treatment is still unanswered. For these patients, radiotherapy combined with hormonal therapy or hormonal therapy alone are recommended. Recently, the reports from NCCB and SEER data showed that radiotherapy combined with hormonal therapy have better survivals than hormonal therapy alone.

This randomized phase III trial compare hormonal therapy alone with combined hormone with radiotherapy in clinically pelvic lymph node metastatic prostate cancer.

03

Conditions studied

  • Prostate Neoplasm

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed prostate cancer within 6 months for study enrollment
  • Clincally enlarged pelvic lymph node ((short axis 0.5 cm ≤) in imaging studies (CT, MRI, PET-CT) at diagnosis and partial response or complete remission of enlarged lymph nodes according to v1.1 after hormonal therapy for 2-3 months 3. age 20 ≤ 4. performance status 0-1 5. Optimal hematologic profiles within 6 months for study enrollment
  • (ANC) ≥ 1500 cells/mm3
  • ≥ 50,000 cells/mm3
  • ≥ 8.0 g/dl 6. Optimal kidney function within 6 months for study enrollment
  • Creatinine \< 2.0 ng/dL 7. Optimal liver functions within 6 months for study enrollment
  • total \< 1.5 X maximum normal value
  • or aspartate aminotransferase \< 2.5 X maximum normal value

Exclusion criteria

Exclusion Criteria:

  1. combined with distant (retroperitoneal lymph node, bone,...)
  2. previous history of antiandrogen therapy within 6 months of study enrollment
  3. previous history of definitive prostate cancer treatment such as prostatectomy
  4. previous history of pelvic radiotherapy
  5. previous history of other cancer treatment except for skin cancer and theroid cancer
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • No intervention
    Hormonal therapy alone

    total androgen ablation or antiandrogen therapy alone for 2-3 years

  • Active comparator
    Hormonal therapy with radiotherapy

    total androgen ablation or antiandrogen therapy for 2-3 years combined with radiotherapy on whole pelvis

    Radiation: Intensity modulated radiotherapy

Interventions

  • RadiationIntensity modulated radiotherapy
06

What researchers measure

Primary outcomes

  1. Comparison of recurrence-free survival between two treatment groups

    expected 5-year recurrence-free survival were 40% in hormonal therapy alone group and more than 80% in hormonal therapy combined with radiotherapy

    Time frame: 5-year

Secondary outcomes

  1. Comparison of toxicities between two treatment groups

    Compare adverse events accroding to CTCAE V4.0 between hormonal therapy alone group and hormonal therapy combined with radiotherapy group

    Time frame: 5-year

  2. Comparison of quality of lifl between two treatment groups

    Compare quality of life accroding to Expanded prostate cancer index composite_Korean between hormonal therapy alone group and hormonal therapy combined with radiotherapy group

    Time frame: 5-year

  3. Comparison of overall survival between two treatment groups

    Compare overall survival between hormonal therapy alone group and hormonal therapy combined with radiotherapy group

    Time frame: 5-year

  4. Comparison of clinical failure free survival between two treatment groups

    Compare clinical failure free survival between hormonal therapy alone group and hormonal therapy combined with radiotherapy group

    Time frame: 5-year

  5. Comparison of cause-specific survival between two treatment groups

    Compare cause-specific survival between hormonal therapy alone group and hormonal therapy combined with radiotherapy group

    Time frame: 5-year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2016 (actual). Primary completion is estimated for Dec 2026, 130 months after the start.

Of 139 non-industry phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 99 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 144. This study's planned 130 months is above that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2017
First posted
Aug 7, 2017
StartActual
Jan 15, 2016
Primary completionEst.
Dec 14, 2026
CompletionEst.
Dec 14, 2026
Last update
Nov 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03241537
Responsible party
Sponsor
First posted
Aug 7, 2017
Start date
Jan 15, 2016
Primary completion
Dec 14, 2026 (estimated)
Completion
Dec 14, 2026 (estimated)
Last update
Nov 27, 2023

Study contacts

Won Park, M.D.,Ph.D
principal investigator · Korean Radiation Oncology Group

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion